-- 据周一提交给澳大利亚证券交易所的文件显示，Chrysos（ASX：C79）今年迄今已签署19份新的PhotonAssay租赁协议，该公司计划在2027财年加速部署这项矿业样品分析技术。 该公司维持了其2026财年的业绩预期，称营收正朝着8000万至9000万澳元预测区间的上限稳步迈进，息税折旧摊销前利润（EBITDA）也有望达到2000万至2700万澳元预期区间的上限。 周一，Chrysos股价上涨1%。
Related Articles
Research
Research Alert: CFRA Maintains Sell Opinion On Ads Of Stellantis N.v.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We reduce our 12-month target price to USD5.80 from USD6.50, which implies a 2027 P/E of 3.5x. The reduction reflects a more cautious earnings outlook following Q1 2026 results, which, while marking a return to profitability, fell short of the pace of recovery we had previously modeled, particularly in the Enlarged Europe segment where persistent pricing headwinds are offsetting volume gains from the Smart Car roll-out. Consequently, we lower our 2026 EPS estimate to EUR0.90 from EUR1.37 and our 2027 estimate to EUR1.43 from EUR2.03. These downward revisions incorporate a larger-than-expected residual drag from prior-year cash charges, tariff impact that will continue to compress North American margins, and a European competitive environment. The sharp cut to our 2027 forecast also acknowledges that the path to a positive free cash flow inflection will demand flawless execution of an ambitious product cadence and cost discipline that the company has yet to demonstrate consistently.
$STLA
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.
$SYK
International
Philippine Manufacturing Activity Contracts as Orders Fall, Costs Rise, S&P Global Says
The Philippines' manufacturing sector slipped into contraction in April as new orders fell sharply and cost pressures intensified, according to data released Monday by S&P Global.The S&P Global Philippines Manufacturing Purchasing Managers' Index fell to 48.3 in April from 51.3 in March, marking the first contraction since November.New orders declined at the fastest pace since August 2021, while export demand weakened further, with firms citing trade route disruptions and halted shipments.Production stalled, and firms cut employment and purchasing activity, drawing down inventories to meet output needs.Input costs rose at the fastest pace since December 2022, driven by higher energy and shipping costs linked to the Middle East war, prompting the sharpest increase in selling prices in 41 months.Supplier delivery times lengthened, while business confidence improved to a 17-month high on expectations of stronger demand ahead.
$^PSEi